Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761198 · ClinicalTrials.gov registry record · Phase 1
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
A Phase 1 study, sponsored by Mereo BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT04761198 is a Phase 1 study that has completed, run by Mereo BioPharma. The registered enrollment target is 76 participants.
The verdict
NCT04761198, a Phase 1 study, has completed, sponsored by Mereo BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).
Interventions
- DRUG Nivolumab
- DRUG Etigilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-03-23 |
| Est. Completion | 2023-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04761198
The ClinicalTrials.gov registry entry for NCT04761198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mereo BioPharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04761198 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04761198 about?
NCT04761198 is a clinical study titled "A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors". This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to rec...
What is the current status of trial NCT04761198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2021-03-23. Estimated completion is 2023-10-30.
What interventions are being tested in trial NCT04761198?
The interventions under investigation include: Nivolumab (DRUG), Etigilimab (DRUG).
Who is sponsoring clinical trial NCT04761198?
This trial is sponsored by Mereo BioPharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.